ATNM - Actinium Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.7918
+0.0089 (+1.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.7829
Open0.8100
Bid0.7600 x 1000
Ask0.0000 x 900
Day's Range0.7700 - 0.8498
52 Week Range0.3320 - 1.0700
Volume2,536,176
Avg. Volume1,551,996
Market Cap87.349M
Beta2.83
PE Ratio (TTM)N/A
EPS (TTM)-0.3320
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.29
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), provided a reminder that it will host a webcast on July 10, 2018 at 8:00 AM ET. The webcast will discuss the Company’s previously announced Actimab-A MRD clinical trial for patients with AML who are in remission but have detectable minimal residual disease (MRD).

  • ACCESSWIRE15 days ago

    Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks

    On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • GlobeNewswire19 days ago

    Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that Dr. Joseph Jurcic, Director of the Hematologic Malignancies Section and Professor of Medicine at Columbia University Medical Center, has initiated Actimab-A MRD, a new clinical trial for patients with AML who are in remission but have detectable minimal residual disease (MRD).  The trial will study the safety/tolerability of Actimab-A in the postremission consolidation setting and include dose finding analyses.  The trial will also study the impact of Actimab-A on minimal residual disease (MRD) as well as progression-free (PFS) and overall survival (OS) rates. The investigational new drug (IND) application for this trial has been cleared by the FDA.

  • GlobeNewswire21 days ago

    Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that it has dosed the 38th patient in the pivotal Phase 3 SIERRA (Study of Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia) study of Iomab-B, reaching twenty-five percent of patient enrollment.  As a result, the trial’s independent Data Monitoring Committee (DMC) will review the trial data at its next meeting, which has been scheduled for August.  The SIERRA trial is a 150 patient, randomized, and controlled multi-center trial that is currently open at 16 leading transplant centers in the US. The Company highlighted the recent initiatives taken to strengthen the outlook for the trial.  Based on the higher than anticipated crossover rate previously announced after the first DMC meeting, the Company deemed it appropriate to increase the number of additional treatment options acceptable for utilization in the control arm.  This was done to accommodate requests from the principal investigators at various sites.  The amended protocol now allows additional treatment options in the control arm including Mylotarg, Venetoclax, and the FLT3 inhibitors Midostaurin and Sorafenib.  Importantly, the Company notes that these treatments may be used based on the preference and discretion of the treating physician in keeping with the design of the study’s control arm and are not approved treatments for this patient population.  The recent protocol changes have been implemented following review by the FDA and IRB approvals.  The Company has also made valuable additions to its clinical organization, including the hiring of Vijay Reddy, M.D., Ph.D., a bone marrow transplant physician with stellar drug development, scientific and clinical experience, as Vice-President of Clinical Development to lead the SIERRA trial.  The Company also materially strengthened its clinical operations group with the addition of two directors, two clinical trial associates and a clinical education and support specialist nurse.  These initiatives taken since the first DMC update have enabled the recent milestone and are expected to ensure the continued strong progress of the SIERRA trial including both site expansion and enrollment.

  • GlobeNewswire21 days ago

    Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting

    Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), today highlighted the Company’s activities at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting that is being held in Philadelphia, Pennsylvania June 23 – 26, 2018. The SNMMI Annual Meeting brings together leading nuclear medicine physicians, scientists, and technologists from the world’s top medical and academic institutions.

  • Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18
    Market Realist27 days ago

    Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18

    On June 18, Actinium Pharmaceuticals (ATNM) stock rose ~25.6% to reach $0.63. The close on June 18 was ~89% higher than its 52-week low of $0.33 on April 24. In the week ended June 15, Actinium Pharmaceuticals stock closed at $0.50, which reflected ~15% growth from the prior week’s close of $0.44 on June 8.

  • GlobeNewswirelast month

    Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M

    -Trial supports Actinium’ s strategic expansion of its CD33 program into novel combinations that can lead to increased use of bone marrow transplants and expand the addressable patient population for this ...

  • How Should You Think About Actinium Pharmaceuticals Inc’s (NYSEMKT:ATNM) Risks?
    Simply Wall St.last month

    How Should You Think About Actinium Pharmaceuticals Inc’s (NYSEMKT:ATNM) Risks?

    If you are a shareholder in Actinium Pharmaceuticals Inc’s (AMEX:ATNM), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • ACCESSWIRElast month

    Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com scans Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences Inc. (NASDAQ: APRI), and Axovant Sciences Ltd (NASDAQ: AXON).

  • GlobeNewswire2 months ago

    Actinium Pharmaceuticals to Present at 19th Annual Bio€quity Europe Conference in Ghent, Belgium

    Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 19th Annual Bio€quity Europe Conference being held on May 14 - 16, 2018 at the Het Pand Convention Center in Ghent, Belgium. Management will conduct one-on-one meetings with investors during the conference.  To arrange a meeting with Actinium, please contact, Steve O’Loughlin, Actinium’s Principal Financial Officer at soloughlin@actiniumpharma.com. Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected presenting companies.

  • GlobeNewswire3 months ago

    Actinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of Directors

    Chell led Be the Match and the National Marrow Donor Program for 17 years establishing these organizations as the largest volunteer bone marrow transplant donor registry in the world that facilitates thousands ...

  • GlobeNewswire3 months ago

    Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development

    Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and Johnson ...

  • ACCESSWIRE3 months ago

    Blog Exposure - Actinium Announces Collaboration with Astellas Pharma

    Stock Monitor: Auris Medical Holding Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM ...

  • ACCESSWIRE5 months ago

    Wired News – Actinium Pharma Announced Activation of Sixteen Clinical Trial Sites in Phase-3 SIERRA Trial for Iomab-B

    Stock Monitor: Magellan Health Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 01, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM ). If ...